{
  "nctrialId": "HC-1747",
  "title": "A  Open-Label, Active-Controlled Multi-Center Study of SCK-880 (Hb polymerization inhibitor) in Patients With Spinal Muscular Atrophy",
  "officialTitle": "A  Open-Label, Active-Controlled Multi-Center Study of SCK-880 (Hb polymerization inhibitor) in Patients With Spinal Muscular Atrophy",
  "sponsor": "Centre for Addiction and Mental Health",
  "indication": "Spinal Muscular Atrophy",
  "phase": "Phase 3",
  "fileName": "HC-1747.json",
  "fileSize": 110521,
  "date": "2023-08-27",
  "completionDate": "2026-05-30",
  "drugName": "SCK-880 (Hb polymerization inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Completed",
  "description": "This is a  open-label, active-controlled multi-center study designed to evaluate the efficacy and safety of SCK-880 (Hb polymerization inhibitor) in patients with Spinal Muscular Atrophy. The study will enroll approximately 314 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 22-79 years\n- Confirmed diagnosis of Spinal Muscular Atrophy\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}